Navigation Links
Anthera Pharmaceuticals Completes Initial Public Offering

HAYWARD, Calif., March 4 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share.  The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any. The sole book-running manager of the offering is Deutsche Bank Securities Inc. Piper Jaffray & Co. is a co-lead manager of the offering and Cowen and Company, LLC and Merriman Curhan Ford & Co. are co-managers of the offering.

Concurrently with the closing of the offering, Anthera completed a private placement of an aggregate of 2,598,780 shares of common stock to certain of its existing investors at a price of $6.58 per share, which is the initial public offering price per share less underwriting discounts and commissions, which will result in net proceeds to Anthera of an additional $17.1 million.  Total net proceeds to Anthera of the initial public offering and the concurrent private placement totaled approximately $53.8 million.

In addition, Anthera issued an aggregate of 531,914 shares of common stock to Eli Lilly and Shionogi and Co., Ltd  in satisfaction of a $3.5 million milestone payment related to the initiation of the VISTA-16 trial for A-002, which Anthera expects to initiate in the near future.

A registration statement relating to the shares of Anthera's common stock offered in the initial public offering has been declared effective by the Securities and Exchange Commission. The initial public offering is being made solely by means of a prospectus. A copy of the final prospectus, when available, can be obtained by contacting: Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email:

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 ready clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease, or CAD. Anthera's Phase 2 ready product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BLyS, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. Anthera has worldwide rights to its product candidates, with the exception of Japan, where Shionogi & Co., Ltd. retains commercial rights to its sPLA2 product candidates.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements relate to future events. These statements are only predictions. The outcome of the events described in these forward-looking statements is subject to risks and uncertainties. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward looking statements.

CONTACT: Juliane Snowden of Burns McClellan, Inc., or 212.213.0006.

SOURCE Anthera Pharmaceuticals, Inc.

Back to top



SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Data From Antheras Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
2. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
3. Biostar Pharmaceuticals, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
4. MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results
5. Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
6. DUSA Pharmaceuticals, Inc.(R) to Host Fourth Quarter and Full Year 2009 Financial Results and Corporate Highlights Conference Call
7. Thomas Pharmaceuticals, Ltd to Merge with Global Medical Equipment of AZ
8. Abbott Completes Acquisition of Solvay Pharmaceuticals
9. Biostar Pharmaceuticals, Inc. Announces Change of Auditor
10. Lotus Pharmaceuticals Announces Key Changes
11. Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009
Post Your Comments:
(Date:11/28/2015)... ... ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, customers ... up to 20% off orders $80 or more to free gifts with purchases, there will ... As a competitive e-commerce website for skin care and cosmetic needs, customers will save on ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... are not changing the way that they are handling security in light of the ... and security presence in an attempt to stop an attack from reaching U.S. soil. ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Lizzie’s Lice Pickers ... company is offering customers 10% off of their purchase of lice treatment product. In ... full price. According to a company spokesperson. “Finding lice is a sure way to ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Wound Care Market by Type (Dressings, Therapy Devices, Active ... Facility, Out-Patient Facility), and Geography - Global Forecast to ... --> --> The purpose of ... forecast of the global advanced wound care market. It ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology: